ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001) Study also met secondary endpoints relating to bone mineral density changes in lumbar ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Alfredo has a PhD in Astrophysics and a Master's in Quantum Fields and Fundamental Forces from Imperial College London.View full profile Alfredo has a PhD in Astrophysics and a Master's in Quantum ...
Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis
(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback